Zacks Small Cap Forecasts Edesa Biotech FY2028 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Investment analysts at Zacks Small Cap issued their FY2028 EPS estimates for shares of Edesa Biotech in a report released on Monday, December 15th. Zacks Small Cap analyst D. Bautz forecasts that the company will post earnings per share of ($0.55) for the year. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share.

Edesa Biotech (NASDAQ:EDSA) last released its earnings results on Friday, December 12th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.80. The firm had revenue of $0.25 million for the quarter.

A number of other research firms also recently weighed in on EDSA. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Edesa Biotech in a research note on Monday, November 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edesa Biotech in a research report on Tuesday, December 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.00.

Edesa Biotech Stock Down 16.1%

Shares of EDSA stock opened at $1.46 on Tuesday. Edesa Biotech has a 12 month low of $1.44 and a 12 month high of $4.49. The firm has a market cap of $10.28 million, a price-to-earnings ratio of -1.08 and a beta of 0.08. The stock has a 50-day moving average price of $2.01 and a 200 day moving average price of $2.16.

Hedge Funds Weigh In On Edesa Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP bought a new position in Edesa Biotech during the 1st quarter worth about $1,678,000. Stonepine Capital Management LLC acquired a new stake in Edesa Biotech in the 1st quarter valued at approximately $1,678,000. Nantahala Capital Management LLC acquired a new stake in Edesa Biotech in the 1st quarter valued at approximately $1,525,000. Finally, Susquehanna International Group LLP bought a new stake in Edesa Biotech in the 3rd quarter valued at approximately $36,000. 5.50% of the stock is owned by institutional investors and hedge funds.

Edesa Biotech Company Profile

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.